Merck & Co. agreed to buy respiratory drugmaker Verona Pharma Plc for around $10 billion as part of its ongoing search for ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Merck, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...